GLP-1 Drugs Improve Outlook For Kidney Transplants

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 6, 2025.

By Dennis Thompson HealthDay Reporter

THURSDAY, March 6, 2025 -- GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study suggests.

The drugs help manage patients’ type 2 diabetes and promote weight loss, both of which improve the chances of a successful kidney transplant, researchers added.

Kidney transplant patients prescribed GLP-1 drugs were 49% less likely to experience organ failure, in which their new kidney stops working and they have to resume dialysis, researchers reported March 3 in The Lancet.

Patients taking GLP-1 drugs also had a 31% lower risk of dying within five years of starting on the medication, researchers said.

“Our study results are the strongest evidence to date that GLP-1 agonist drugs are largely safe and effective tools for addressing type 2 diabetes in kidney transplant recipients,” lead researcher Dr. Babak Orandi said in a news release. He's a transplant surgeon and obesity medicine specialist at NYU Langone Health in New York City.

Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food.

GLP-1 drugs include semaglutide, liraglutide and dulaglutide, now marketed as Ozempic, Wegovy, Saxenda, Victoza and Trulicity.

Both diabetes and obesity increase the risk of a kidney transplant going bad, researchers said. Given that, it makes sense that GLP-1 drugs might help.

However, known side effects of the drugs include inflammation of the pancreas and liver problems, which might work against a kidney transplant, researchers noted.

There’s also been concern that GLP-1 drugs might increase the risk of a rare form of thyroid cancer in patients taking immune-suppressing drugs to prevent transplant rejection, researchers added.

To check the risks and benefits of the drugs, researchers reviewed the medical records of more than 18,000 kidney transplant recipients with diabetes between 2013 and 2020.

Of those, more than 1,900 had been prescribed a GLP-1 drug.

Although the study found benefits, it also discovered some increased risks associated with the drugs.

Kidney transplant patients taking GLP-1 drugs had a 49% greater risk of developing diabetic retinopathy, a potentially blinding condition caused by damage to the light-sensitive tissue lining the back of the eyes.

“Our findings also show that while the benefits of GLP-1 drugs are significant, their use does come with some added risk of diabetic retinopathy, suggesting that physicians need to carefully monitor the eye health of kidney transplant recipients with diabetes who are started on these drugs,” senior investigator Mara McAdams-DeMarco said in a news release. She is an associate professor of surgery and population health at NYU Grossman School of Medicine.

Orandi said this risk can be managed by screening for diabetic retinopathy in transplant patients, particularly in people with uncontrolled diabetes, and making sure blood sugar levels are stable before prescribing GLP-1 drugs.

Doctors also might consider starting with lower doses of GLP-1 drugs and slowly increasing them for people with severe diabetes or a history of eye problems, he added.

More research is needed to figure out exactly why GLP-1 drugs might help kidney transplants succeed, as well as why they increase the risk of diabetic retinopathy, researchers concluded.

Sources

  • NYU Langone Health, news release, March 5, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-03-07 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords